Development and Validation of an UPLC-QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan-KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies.
Daraxonrasib, an orally administered pan-RAS inhibitor, is undergoing clinical evaluation for pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Defining its pharmacokinetic profile is therefore critical for ongoing progress. Accordingly, a simple and sensitive UPLC-QqQ-MS/MS assay was...